Executive Profile*

Seth A. Rudnick M.D.

Chairman and Scientific and Clinical Advisor,G1 Therapeutics, Inc.
AgeTotal Calculated CompensationThis person is connected to 105 board members in 12 different organizations across 20 different industries.

See Board Relationships
67$154,503

Background*

Dr. Seth A. Rudnick, M.D., serves as the Chairman and Scientific and Clinical Advisor of G1 Therapeutics, Inc. since January 7, 2014. Dr. Rudnick has been the Chairman of Liquidia Technologies Inc. since March 11, 2008. He serves as the Chairman of ORTHOCON Inc, Drug Innovation Ventures at Emory (DRIVE) and Meryx Inc. He has been a Director of Liquidia Technologies, Inc. since 2006, Square 1 Financial Inc. since November 2012, Aralez Pharmaceuticals Inc. (Pozen Inc.) ...

Read Full Background

Corporate Headquarters*

79 T.W. Alexander Drive
Research Triangle Park, North Carolina 27709

United States

Phone: 919-213-9835
Fax: 919-741-5830

Board Members Memberships*

Director
Director
Chairman
Director
2001-Present
Director
2006-Present
Chairman
2008-Present
Chairman of the Board
2013-Present
Director
2014-Present
Chairman and Scientific and Clinical Advisor

Education*

BA
University of Pennsylvania
MD
University of Virginia
MD
Washington University, St. Louis
Post-Doctoral Training
Yale University

Other Affiliations*

Annual Compensation*

There is no Annual Compensation data available.

Stock Options*

There is no Stock Options data available.

Total Compensation*

Total Annual Cash Compensation$74,500
Total Calculated Compensation$154,503
*Data is at least as current as the most recent Definitive Proxy.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Paul V. Campanelli Chief Executive Officer, President and Director
Endo International plc
$272.4K
Daniel N. Swisher Jr.Chief Executive Officer, President and Director
Sunesis Pharmaceuticals, Inc.
$498.3K
Andrew Philip Witty Chief Executive Officer and Executive Director
GlaxoSmithKline plc
3.3M GBP
Kenneth C. Frazier Chairman, Chief Executive Officer and President
Merck & Co., Inc.
$1.5M
Pascal Soriot Chief Executive Officer, Executive Director and Member of Disclosure Committee
AstraZeneca PLC
3.2M GBP
Compensation as of Fiscal Year 2015.

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.